Osteosarcoma represents the most frequent malignant primary bone tumor, which mainly occurs in children and adolescents and causing high mortality. To date, despite significant advancements in the diagnosis and treatment of the cancer, long-term survival in both localized and metastatic osteosarcoma is still stagnated. Thus, conventional therapy is not fully adequate for osteosarcoma treatment and novel therapeutic approaches are required to improve outcomes.
